105 related articles for article (PubMed ID: 480011)
1. The use of plasma androstenedione in monitoring therapy of patients with congenital adrenal hyperplasia.
Cavallo A; Corn C; Bryan GT; Meyer WJ
J Pediatr; 1979 Jul; 95(1):33-7. PubMed ID: 480011
[TBL] [Abstract][Full Text] [Related]
2. Plasma progesterone, 17-hydroxyprogesterone, androstenedione and testosterone in prepubertal, pubertal and adult subjects with congenital virilizing adrenal hyperplasia as indicators of adrenal suppression.
Lee PA; Urban MD; Gutai JP; Migeon CJ
Horm Res; 1980; 13(6):347-57. PubMed ID: 7196877
[TBL] [Abstract][Full Text] [Related]
3. Plasma androgens in congenital adrenal hyperplasia: androstenedione concentration as an index of adrenal androgen suppression.
Keenan BS; McNeel R; Barrett GN; Holcombe JH; Kirkland RT; Clayton GW
J Lab Clin Med; 1979 Nov; 94(5):799-808. PubMed ID: 159330
[No Abstract] [Full Text] [Related]
4. [Value of the assay of plasma steroids in the control of congenital adrenal hyperplasia].
Theintz GE; Sizonenko PC
Arch Fr Pediatr; 1985 Mar; 42(3):211-7. PubMed ID: 4004483
[TBL] [Abstract][Full Text] [Related]
5. Alternate day prednisone therapy in congenital adrenal hyperplasia: adrenal androgen suppression and normal growth.
Linder B; Feuillan P; Chrousos GP
J Clin Endocrinol Metab; 1989 Jul; 69(1):191-5. PubMed ID: 2543690
[TBL] [Abstract][Full Text] [Related]
6. Urinary and serum steroid concentrations in the management of congenital adrenal hyperplasia. Lack of physiologic correlations.
Hendricks SA; Lippe BM; Kaplan SA; Lavin N; Mayes DM
Am J Dis Child; 1982 Mar; 136(3):229-32. PubMed ID: 7064949
[TBL] [Abstract][Full Text] [Related]
7. Plasma 3 alpha-androstanediol glucuronide in normal children and in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Lopes LA; Catzeflis C; Cicotti I; Rey C; Sizonenko PC
Horm Res; 1997; 48(1):35-40. PubMed ID: 9195208
[TBL] [Abstract][Full Text] [Related]
8. 17-hydroxyprogesterone, androstenedione, and testosterone in normal children and in prepubertal patients with congenital adrenal hyperplasia.
von Schnakenburg K; Bidlingmaier F; Knorr D
Eur J Pediatr; 1980 May; 133(3):259-67. PubMed ID: 7389739
[TBL] [Abstract][Full Text] [Related]
9. Inappropriate adrenal androgen secretion with once-a-day corticosteroid therapy for congenital adrenal hyperplasia.
Keenan BS; Eberle AE; Lin TH; Clayton GW
J Pediatr; 1990 Jan; 116(1):133-6. PubMed ID: 2153199
[TBL] [Abstract][Full Text] [Related]
10. [Use of steroid indicators in monitoring the treatment of congenital adrenal hyperplasia].
Sulcová J; Lisá L; Dvorák P; Hampl R; Stárka L
Cesk Pediatr; 1990 Jun; 45(6):353-6. PubMed ID: 2289256
[TBL] [Abstract][Full Text] [Related]
11. Variable efficacy of glucocorticoids in congenital adrenal hyperplasia.
Hansen JW; Loriaux DL
Pediatrics; 1976 Jun; 57(6):942-7. PubMed ID: 934750
[TBL] [Abstract][Full Text] [Related]
12. A bloodspot androstenedione assay suitable for home-monitoring of steroid replacement therapy in congenital adrenal hyperplasia.
Egan SM; Betts P; Thomson S; Wallace AM; Wood PJ
Ann Clin Biochem; 1989 May; 26 ( Pt 3)():262-7. PubMed ID: 2669617
[TBL] [Abstract][Full Text] [Related]
13. Androstenedione rhythms in saliva in congenital adrenal hyperplasia.
Young MC; Walker RF; Riad-Fahmy D; Hughes IA
Arch Dis Child; 1988 Jun; 63(6):624-8. PubMed ID: 3389892
[TBL] [Abstract][Full Text] [Related]
14. 3 alpha-androstanediol glucuronide in virilizing congenital adrenal hyperplasia: a useful serum metabolic marker of integrated adrenal androgen secretion.
Pang S; MacGillivray M; Wang M; Jeffries S; Clark A; Rosenthal I; Wiegensberg M; Riddick L
J Clin Endocrinol Metab; 1991 Jul; 73(1):166-74. PubMed ID: 2045467
[TBL] [Abstract][Full Text] [Related]
15. Correlation between androstenedione and 17-hydroxyprogesterone levels in the saliva and plasma of patients with congenital adrenal hyperplasia.
Juniarto AZ; Goossens K; Setyawati BA; Drop SL; de Jong FH; Faradz SM
Singapore Med J; 2011 Nov; 52(11):810-3. PubMed ID: 22173250
[TBL] [Abstract][Full Text] [Related]
16. Treatment of congenital virilizing adrenal hyperplasia patients with single and multiple daily doses of prednisone.
Huseman CA; Varma MM; Blizzard RM; Johanson A
J Pediatr; 1977 Apr; 90(4):538-42. PubMed ID: 839364
[TBL] [Abstract][Full Text] [Related]
17. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency).
Gasparini N; Di Maio S; Salerno M; Argenziano A; Franzese A; Tenore A
Horm Res; 1997; 47(1):17-22. PubMed ID: 9010713
[TBL] [Abstract][Full Text] [Related]
18. Androstenedione and its conversion to plasma testosterone in congenital adrenal hyperplasia.
Horton R; Frasier SD
J Clin Invest; 1967 Jun; 46(6):1003-9. PubMed ID: 4290686
[TBL] [Abstract][Full Text] [Related]
19. Hormonal and clinical responses to prednisone treatment in adolescents with congenital adrenal hyperplasia.
Zipf WB; Bacon GE; Kelch RP
Horm Res; 1980; 12(4):206-17. PubMed ID: 6446517
[TBL] [Abstract][Full Text] [Related]
20. Serum androgens as a continuing index of adequacy of treatment of congenital adrenal hyperplasia.
Korth-Schutz S; Virdis R; Saenger P; Chow DM; Levine LS; New MI
J Clin Endocrinol Metab; 1978 Mar; 46(3):452-8. PubMed ID: 156192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
